WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (the “Company”) (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, has been featured in several media outlets that spotlighted the Company and the SENSUS™ Pain Management System. SENSUS is a convenient and wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is optimally designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to five million people in the U.S. alone.
NeuroMetrix is referenced in the article “What ‘Smart Fabrics’ Mean for the Future of Health” on Healthline.com, a consumer-focused health site. The article highlights SENSUS as part of the growing trend of wearable technology. Shai Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix is quoted: “The notion of smart wearable technology is expanding...It’s exciting for people who have health needs because it makes delivering therapy easier and more successful for patients...That’s the ultimate desired outcome.” To read the article, please visit the following link: http://www.healthline.com/health-news/tech-smart-fabrics-future-of-health-011614
Dr. Gozani was interviewed on Allie's Voice, an influential diabetes blog focusing on medical advancements and research to improve the quality of life for people with diabetes. To read the interview, please visit the following link: http://www.alliesvoice.com/2014/01/17/sensus-pain-management-system/
Dr. Gozani was also interviewed on Your Family's Health on 90.3 FM, a radio show based in the Long Island, New York area. During the program, Dr. Gozani provided an overview of peripheral neuropathy and its effect on cost, lifestyle and health. The second half of the show focused on SENSUS as an attractive therapy option for patients with painful neuropathy. To listen to the interview in its entirety, please visit the following link: http://www.sensusrx.com/about-neurometrix/news-and-events/your_family's_healtlh__peripheral_neuropathy._dr_shai_gozani_nmp3.mp3
A recent article in MedCity News titled “Wearable diabetic neuropathy pain management system strives for simplicity” provides an overview of SENSUS and highlights the device’s simple design. Dr. Gozani is quoted: “We wanted to make this as easy to use as taking a pill. Because really that’s the alternative in a sense–a pain pill. . . . The last thing they need is another complicated device to try to manage everything else going on in their lives.” To read the article, please visit the following link: http://medcitynews.com/2013/11/wearable-diabetic-neuropathy-treatment-pain-management-strives-one-button-simplicity/#
Lastly, Diabetes Self-Management listed SENSUS as one of the “Tools of the Trade 2013.” Diabetes Self Management is a publisher of authoritative, reliable health information for the growing number of people with diabetes who want to know more about controlling and managing their diabetes. To read the article, please visit the following link: http://medcitynews.com/2013/11/dave-eggers-circle-future-of-healthcare-big-data-digital-health/
NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. The Company is presently focused on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company also markets the DPNCheck® device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visit http://www.neurometrix.com.